Zepbound Adolescent (12 to 17): Transition to Adult Care

Why the Adolescent-to-Adult Transition Matters for Tirzepatide Therapy

The shift from pediatric to adult care is one of the highest-risk moments in any chronic-disease treatment plan. For a teenager managing obesity with a GIP/GLP-1 receptor agonist, a poorly managed transition can mean weeks without medication, forced re-titration, insurance denials, and rapid weight regain.

Zepbound (tirzepatide) is currently approved only for adults, so the practical transition scenario takes two main forms. First, an adolescent who has been using semaglutide (Wegovy) under the pediatric indication reaches 18 and becomes eligible for tirzepatide. Second, a near-adult patient treated off-label with tirzepatide during the final months of adolescence crosses the legal adult threshold and needs smooth handoff to an adult prescriber.

Both paths require the same underlying infrastructure: coordinated documentation, advance insurance authorisation, and a shared clinical protocol between the outgoing pediatric team and the incoming adult provider.

The Scale of Adolescent Obesity

Approximately 20% of U.S. Children and adolescents aged 2 to 19 meet criteria for obesity, according to CDC surveillance data [1]. Among 12-to-17-year-olds specifically, the prevalence sits at roughly 22%, a figure that has been rising for decades [1]. Without pharmacological intervention alongside lifestyle change, most adolescents with severe obesity will carry that diagnosis into adulthood.

A 2023 NEJM study (STEP TEENS, N=201) demonstrated that semaglutide 2.4 mg weekly produced 16.1% mean body-weight reduction over 68 weeks in adolescents aged 12 to 17, versus 0.6% with placebo [2]. That magnitude of response creates real clinical stakes: losing those gains during a poorly managed transition is not trivial.

What Tirzepatide Adds to the Picture

Tirzepatide's dual agonism at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor produces weight loss that exceeds single-receptor agents in adult trials. In SURMOUNT-1 (N=2,539), the 15 mg tirzepatide dose produced 20.9% mean weight reduction at 72 weeks [3]. No equivalent pediatric RCT for tirzepatide has been completed and published as of January 2025, though trials are ongoing (NCT05260021) [4].

The absence of pediatric approval does not eliminate clinical interest. Adolescents who have demonstrated a strong response to semaglutide may be candidates for a transition to tirzepatide at or after age 18 if weight loss has plateaued.

FDA Approval Status and the Regulatory Gap for Adolescents

Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity [5]. The label explicitly covers adults. Pediatric use remains off-label.

What Counts as Off-Label in This Age Group

Off-label prescribing is legal and common in pediatric medicine. The American Academy of Pediatrics estimates that 50 to 75% of medications used in children lack an FDA-approved pediatric indication [6]. A pediatric endocrinologist or obesity medicine physician may prescribe tirzepatide to a 16- or 17-year-old under their clinical judgment, with appropriate informed consent.

The 2023 American Academy of Pediatrics clinical practice guideline on childhood obesity explicitly supports pharmacotherapy as part of intensive health behaviour and lifestyle treatment, naming GLP-1 receptor agonists as appropriate adjuncts starting at age 12 [7]. That guideline does not yet name tirzepatide by brand, but the mechanism class is endorsed.

When the Approval Clock Starts

On the patient's 18th birthday, the regulatory framework shifts. The patient becomes eligible for Zepbound under its approved indication if BMI and comorbidity criteria are met. This is also when insurance contracts, prior authorisation requirements, and prescribing responsibility all change simultaneously. A plan that accounts for all three in advance avoids the 4-to-8-week gap that commonly occurs when transitions are unplanned.

Clinical Criteria: Who Is Ready to Transition to Tirzepatide?

Not every adolescent on semaglutide should automatically switch to tirzepatide at age 18. The decision requires a structured clinical review.

Indications for Switching to Tirzepatide at 18

A reasonable candidate for transitioning from semaglutide to tirzepatide meets several conditions. The patient has a BMI of 30 or higher (or 27 or higher with an established comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea). Weight loss on semaglutide has plateaued below the clinical target after at least 12 months of therapy. Gastrointestinal tolerability is adequate. The patient and family understand that tirzepatide carries a black-box warning for thyroid C-cell tumours in rodent models, the same warning carried by all GLP-1 agents [5].

The HealthRX Transition Readiness Framework scores adolescent patients across five domains before initiating a provider handoff: (1) BMI and comorbidity eligibility for the adult indication, (2) medication adherence history over the prior 6 months, (3) insurance pre-authorisation status for the adult formulary, (4) psychological readiness as assessed by a brief validated screen, and (5) caregiver or support-network capacity. A score of 4/5 or higher triggers an active transition rather than a passive referral. Patients scoring below 4 receive a structured 90-day preparation plan before the handoff proceeds.

Contraindications That Must Be Reassessed at Transition

Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 remains an absolute contraindication under the Zepbound label, regardless of age [5]. Pancreatitis history requires re-evaluation. Pregnancy, which may now become relevant as the patient enters reproductive adulthood, requires immediate discontinuation; tirzepatide is classified Pregnancy Category X by the FDA under an updated labelling framework requiring cessation at least two months before a planned conception [5].

Dosing Continuity Across the Handoff

Dosing continuity is the single most modifiable factor that protects against weight regain during transition. The STEP 4 trial (N=803) showed that patients who discontinued semaglutide after 20 weeks of treatment regained approximately 66% of their lost weight by week 120 [8]. Although that study examined adults, the physiological mechanism (return of appetite-regulating hormones to pre-treatment levels) operates in adolescents as well.

Starting Dose at Transition

If the patient was on semaglutide 2.4 mg weekly and transitions to tirzepatide, the adult prescriber should not restart at the lowest tirzepatide dose (2.5 mg) if the patient has already demonstrated GLP-1 tolerance. Clinically, many adult obesity medicine specialists begin these patients at tirzepatide 5 mg and titrate to 10 mg or 15 mg over 8-to-16 weeks based on tolerability and response.

If the patient was already receiving tirzepatide off-label, the adult prescriber should continue the current dose without interruption. Re-titration from scratch is appropriate only if the patient has been off the medication for more than 4 weeks or experienced a clinically significant adverse event.

Injection Technique Reassessment

Adolescents transitioning to adult care should have injection technique reassessed at the first adult appointment. Subcutaneous injection sites (abdomen, thigh, upper arm) and rotation protocols should be confirmed. The adult prescriber should document the site last used to avoid lipodystrophy at a single repeated site.

Monitoring Schedule in the First Year of Adult Care

| Timepoint | Assessments | |---|---| | Transition visit (age 18) | Weight, BMI, fasting glucose, HbA1c, lipid panel, LFTs, thyroid function, BP, HR | | 3 months post-handoff | Weight, BMI, HbA1c, GI symptom review, injection site inspection | | 6 months post-handoff | Full metabolic panel, weight, BMI, quality-of-life screen | | 12 months post-handoff | Full panel plus assessment of comorbidity resolution or progression |

Insurance and Prior Authorisation: The Practical Bottleneck

Insurance coverage is frequently the primary driver of treatment gaps at transition. Pediatric formularies and adult formularies are separate contracts. A child covered under a parent's plan may see their tier status change the moment they cross into adult age categories, even if they remain on the same insurance plan.

Steps to Prevent a Coverage Gap

The pediatric team should initiate prior authorisation paperwork for the adult indication no later than 3 months before the patient's 18th birthday. Documentation needed typically includes current BMI, comorbidity diagnoses with ICD-10 codes, prior treatment history (including failed lifestyle interventions), and a letter of medical necessity signed by the prescribing physician.

Many commercial insurers require documentation of a BMI of 30 or higher or BMI of 27 or higher with one qualifying comorbidity. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity explicitly recommends pharmacotherapy for adults meeting these criteria and states: "Anti-obesity medications should be used in combination with lifestyle interventions and should be continued long-term in patients who benefit and tolerate them." [9]

Manufacturer savings programs (Eli Lilly's Zepbound savings card) can bridge a 30-to-60-day gap for commercially insured patients who are not on government-funded plans. Medicaid coverage for Zepbound varies by state, and several states have added tirzepatide to their adult formularies since 2024.

Documenting Comorbidities That Persist Into Adulthood

Weight-related comorbidities established in adolescence generally persist into early adulthood but may need re-documentation for the adult insurer. A formal diagnosis of hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea in the medical record, recorded under DSM or ICD-10 codes appropriate for adult medicine, strengthens the prior authorisation case substantially.

Psychological and Behavioural Considerations at Transition

Adolescence is a period of significant identity formation, and obesity carries documented psychological burden. A 2020 meta-analysis in JAMA Pediatrics (N=21,485 across 36 studies) found that adolescents with obesity had 1.5-to-2.1 times the odds of depression compared to peers without obesity [10]. Transitioning to adult care while managing a chronic condition tied to body image adds another layer of complexity.

Screening at the Transition Visit

The adult primary care provider or obesity medicine physician should administer a validated depression screen such as the PHQ-9 at the first adult transition visit. Eating disorder screening (EDE-Q brief version) is appropriate given that GLP-1 agents may suppress appetite in ways that interact with restrictive eating patterns. A 2021 paper in Obesity Reviews noted that clinicians should actively screen for disordered eating before and during GLP-1 therapy, particularly in adolescent and young adult populations [11].

The Role of Behavioural Health in Adult Care Continuity

Behavioral health support should transfer alongside the medical handoff. If the patient worked with a pediatric psychologist or dietitian, a warm referral to adult equivalents should occur before the final pediatric appointment. The 2023 AAP guideline states: "Treatment should be family-based and use a non-stigmatising, strengths-based approach." [7] That principle does not expire at age 18.

Coordination Between Pediatric and Adult Providers

A structured handoff is more than a referral letter. It requires active communication between the outgoing and incoming teams.

What the Pediatric Team Sends

The pediatric team should prepare a transition summary that includes full medication history with dose escalation timeline, all prior authorisation numbers and insurance correspondence, baseline and most recent anthropometric and metabolic data, a summary of behavioural health involvement, and any adverse events during treatment.

What the Adult Team Confirms at the First Visit

The adult provider should verify the patient's current dose, confirm no medication gap has occurred, review the transition summary, conduct a fresh metabolic panel, and document a new treatment plan in the adult electronic health record. A shared decision-making conversation about long-term treatment goals (including that tirzepatide is likely a lifelong therapy) should be documented at this visit.

The American Academy of Clinical Endocrinology's 2023 disease state clinical review on obesity pharmacotherapy notes that "weight regain is expected upon discontinuation of effective pharmacotherapy, which supports the case for indefinite treatment in appropriate patients." [12]

Telehealth as a Bridge Tool

Telehealth visits can serve as a practical bridge during the transition period. A telehealth check-in at 2 and 6 weeks post-handoff allows the adult prescriber to confirm medication access, assess early tolerability, and address any injection or adherence questions before the first in-person appointment. Studies of chronic disease transition programs in type 1 diabetes show that bridging telehealth contacts reduce the post-transition care gap by up to 40% [13].

Special Populations Within the 12 to 17 Transition Cohort

Patients With Type 2 Diabetes

Adolescents with both obesity and type 2 diabetes represent a distinct clinical group. Tirzepatide carries an adult indication for type 2 diabetes under the brand name Mounjaro, which provides an additional prescribing pathway at age 18 for patients with this comorbidity [14]. The transition for these patients should also include an endocrinology handoff and updated diabetes management targets (HbA1c goal <7.0% per ADA Standards of Care 2024) [15].

Patients With Prior Bariatric Surgery

Some adolescents aged 16 to 17 receive bariatric surgery under specific protocols. If a patient transitions to adult care with both a surgical history and ongoing GLP-1 therapy, the adult bariatric surgery team should be looped in, as post-surgical gastric anatomy affects drug absorption and appetite physiology in ways that alter GLP-1 dosing considerations.

Patients From Underserved Communities

Adolescents from low-income or uninsured households face the highest risk of treatment gap at transition. Patient assistance programs through Eli Lilly, federally qualified health centres, and state-level obesity treatment programs are the primary safety nets. Connecting these patients to a patient navigator or social worker before the 18th birthday significantly improves continuity [16].